Efficacy and Safety of RET-Specific Kinase Inhibitors in RET-Altered Cancers: A Systematic Review

Ali, MA; Shah, SS; Ali, R; Bajwa, SF; Rehman, S; Anwar, A; Anwar, MY; Saeed, M; Mirza, N; Aiman, W

Shah, SS (通讯作者)，1000 S Limestone, Lexington, KY 40536 USA.

CANCER INVESTIGATION, 2023; 41 (8): 739

Abstract

RET proto-oncogene encodes receptor tyrosine kinase. Selpercatinib and pralsetinib are the only RET-specific tyrosine kinase inhibitors approved by FD......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索